AI assistant
Rua Bioscience Limited — Capital/Financing Update 2025
May 13, 2025
66262_rns_2025-05-13_09c8d203-fd36-443f-a7cb-d71df9c25aca.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
CORPORATE ACTION
==> picture [125 x 73] intentionally omitted <==
FOR PUBLIC RELEASE
NZX Limited Wellington
13 May 2025
Rua Bioscience approves debt loan facility to accelerate sales growth.
The Board of Rua Bioscience have approved a debt facility offered to wholesale lenders for the purchase of stock to accelerate sales growth. As Rua Bioscience expands globally, the requirements for working capital has increased. This facility provides for up to $2mill additional working capital for the purchase of inventory for significant sales growth.
As part of this facility, the Board has resolved to issue up to 5% of the shares on issue as Warrants to subscribe for fully paid ordinary shares of Rua.
Key terms of the Warrant issue are as follows:
==> picture [412 x 195] intentionally omitted <==
----- Start of picture text ----- Number of Warrants Up to a maximum of 11,182,401 warrants for a maximum$2mill debt facility.Exercise Price $0.015 per fully paid ordinary share to be issued onexercise of each Warrant.Vesting Date 12 months following Commencement DateMaturity Date 3 years following Commencement DateExercise Period Warrants are exercisable at any time following VestingDate and prior to Maturity Date.Other Warrants are not to be quoted or tradeable/transferrable.----- End of picture text -----
The Warrants will be issued to wholesale lenders identified by the Board, with the issue and allotment to occur as funds are made available to Rua.
Strategic alignment with growth objectives
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
This debt facility is a pivotal part of Rua growth strategy, aimed at accelerating its market penetration and significantly scaling revenues. By securing flexible working capital, Rua is reinforcing its ability to meet the rising demand for its medicinal cannabis products across domestic and international markets.
ENDS
The person who authorised this announcement:
Paul Naske Chief Executive Officer [email protected] +64 21 445154
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com